False-positive amphetamineecstasy (MDMA3,4-methylenedioxymethamphetamine) (CEDIA) and ecstasy (MDMA3,4-methylenedioxymethamphetamine) (DRI) test results with fenofibrate.
This case report describes a false-positive amphetamineecstasy 3,4-methylenedioxymethamphetamine (MDMA) and ecstasy (MDMA) screen after therapeutic use of antihyperlipidemic drug, fenofibrate. A 60-year-old male patient was admitted to inpatient psychiatry unit with the diagnosis of alcohol dependency. He was prescribed diazepam 30 mgday, thiamine 300 mgday, and naltrexone 50 mgday. He had also been using fenofibrate 267 mgday for 3 years for hyperlipidemia and trazodone 100 mgday for 5 months for insomnia. On routine, urine drugs-of-abuse screening amphetamineMDMA (CEDIA) test was positive for 4 different occasions and MDMA (DRI) test was positive on 5 different occasions. Gas chromatographymass spectrometry confirmation of the first positive 3 samples were negative for amphetamine and MDMA. After discontinuation of fenofibrate, amphetamineMDMA, and MDMA immunoassay results turned out to be negative. Caution should be given to interpretation of amphetamineMDMA (CEDIA) and MDMA (DRI) tests in patients taking fenofibrate. Specific confirmation with a suitable method should be used to prevent erroneous interpretations.